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ABSTRACT
Objectives: To examine the association between
submaximal cardiorespiratory fitness (sCRF) and all-
cause mortality in a cardiac rehabilitation (CR) cohort.
Design: Retrospective cohort study of participants
entering CR between 26 May 1993 and 16 October
2006, followed up to 1 November 2013 (median
14 years, range 1.2–19.4 years).
Setting: A community-based CR exercise programme
in Leeds, West Yorkshire, UK.
Participants: A cohort of 534 men (76%) and 136
women with a clinical diagnosis of coronary heart
disease (CHD), aged 22–82 years, attending CR were
evaluated for the association between baseline sCRF
and all-cause mortality. 416 participants with an
exercise test following CR (median 14 weeks) were
examined for changes in sCRF and all-cause mortality.
Main outcome measures: All-cause mortality and
change in sCRF expressed in estimated metabolic
equivalents (METs).
Results: Baseline sCRF was a strong predictor of all-
cause mortality; compared to the lowest sCRF group
(<5 METs for women and <6 METs for men), mortality
risk was 41% lower in those with moderate sCRF (HR
0.59; 95% CI 0.42 to 0.83) and 60% lower (HR 0.40;
95% CI 0.25 to 0.64) in those with higher sCRF levels
(≥7 METs women and ≥8 METs for men). Although
improvement in sCRF at 14 weeks was not associated
with a significant mortality risk reduction (HR 0.91;
95% CI 0.79 to 1.06) for the whole cohort, in those
with the lowest sCRF (and highest all-cause mortality)
at baseline, each 1-MET improvement was associated
with a 27% age-adjusted reduction in mortality risk
(HR 0.73; 95% CI 0.57 to 0.94).
Conclusions: Higher baseline sCRF is associated with
a reduced risk of all-cause mortality over 14 years in
adults with CHD. Improving fitness through exercise-
based CR is associated with significant risk reduction
for the least fit.
INTRODUCTION
The prognostic importance of cardiorespira-
tory ﬁtness (CRF), as determined by direct
measurement or prediction of maximal
oxygen uptake (VO2 max), in men and
women with coronary heart disease (CHD)
has been widely reported within epidemio-
logical studies.1–4 The ﬁtness-mortality rela-
tionship has been shown to be non-linear,
with the greatest mortality risk observed
among the least ﬁt.5–7 Findings from the
Cardiac Wellness Institute of Calgary have
recently demonstrated that each 1-metabolic
equivalents (MET) improvement in CRF
achieved during cardiac rehabilitation (CR)
is associated with signiﬁcant additional risk
reduction for patients with the lowest CRF
levels.6 Accordingly, improving low levels of
CRF in patients undertaking exercise-based
CR is potentially an important therapeutic
goal.
Studies examining mortality and CRF out-
comes from UK CR programmes are
sparse.8 9 The largest randomised clinical
trial of CR in the UK reported no survival
Strengths and limitations of this study
▪ Most detailed evaluation of prognostic risk asso-
ciated with baseline and short-term submaximal
cardiorespiratory fitness (sCRF) changes follow-
ing exercise-based cardiac rehabilitation (CR)
within a UK cohort.
▪ Longest complete follow-up of survival data
among unselected male and female participants
within a community-based CR cohort.
▪ Risk estimates for all-cause mortality associated
with sCRF adjusted for numerous confounders,
including coronary heart disease diagnosis, car-
diovascular disease and other comorbidities,
exercise test abnormalities, secondary prevention
medications and self-report physical activity.
▪ Use of submaximal exercise test termination cri-
teria and exercise capacity assessment is limited
compared to direct measurement (or estimation)
of maximal oxygen uptake (VO2 max) from
maximal exercise testing.
▪ Reasons for non-completion of CR not routinely
monitored or recorded.
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beneﬁt from CR, though importantly, it did not consider
changes in patients’ CRF levels.10 A previous inter-
national meta-analysis has suggested mean CRF improve-
ments of 1.6 METs following CR, though it did not
include data from the UK.11 In contrast, the estimated
mean MET change determined from submaximal testing
during supervised exercise training across four UK
centres was 0.5 MET;8 though the exercise prescription
in these centres was conservative by European stan-
dards.12 Thus, whether this magnitude of CRF change is
representative of typical UK CR is not known.
To the best of our knowledge, only one recent study
has investigated the factors predicting long-term survival
(including the role of CRF) within the UK CR setting.9
However, importantly, it did not quantify CRF change or
associated mortality risk estimates across the CRF distri-
bution. An improved understanding of these associations
may help UK clinicians and CR practitioners to better
determine the efﬁcacy of CR for mortality risk reduction
and the clinical beneﬁt of CRF improvement for
patients. The objectives of this study were therefore to:1
examine the association between baseline CRF and all-
cause mortality from routine submaximal exercise test
data collected from a community exercise-based CR
cohort;2 evaluate short-term changes in submaximal
CRF (sCRF) following CR; and3 examine the mortality
risk reduction associated with sCRF changes, with spe-
ciﬁc reference to those with the lowest sCRF levels at CR
entry.
METHODS
Setting and participants
This is a retrospective cohort study of participants enter-
ing a community-based CR exercise programme, ‘Heart
Watch’, delivered by local council leisure services in
Leeds, UK, between 26 May 1993 and 16 October 2006.
All participants were enrolled with a clinical diagnosis of
CHD and classiﬁed as follows: previous myocardial infarc-
tion (MI), previous revascularisation therapy (including
coronary artery bypass grafting (CABG) or percutaneous
coronary intervention (PCI). Programme enrolment was
made on the basis of general practitioner or consultant
cardiologist/CR nurse referral. Participants were clinic-
ally stable and discharged from hospital for a minimum
of 12 weeks.
Data sources and measurement
Mortality status was ascertained from date of death from
clinical databases (Leeds Teaching Hospitals’ National
Health Service (NHS) Trust) that use established
tagging procedures provided by NHS registers in
England. These databases were accessed using personal
identiﬁers (full name, date of birth, postcode) to
provide secure data linkage with the Heart Watch data
registry.
The Heart Watch database has captured medical and
exercise testing and training data for all participants
enrolled in the programme since 1993. At enrolment,
routinely collected data include: date of entry, age, sex,
postcode, marital status, aetiology of CHD disease,
family history, previous cardiac history and procedures
(eg, CABG, PCI), cardioprotective medications, smoking
status (categorised as never, <10 years and >10 years ces-
sation and current), and comorbidities including: dia-
betes mellitus, hypertension, chronic heart failure,
cerebrovascular disease, valvular disease and peripheral
vascular disease. Cardiovascular risk factor measure-
ments include waist circumference, body mass index
(BMI), blood pressure and lipid proﬁle. New paragraph
required here Body mass and height were recorded and
BMI was calculated as mass (kg) divided by stature
squared (m2). Manual arm-cuff sphygmomanometry was
used for all resting blood pressure assessments. sCRF
measurements included: exercise duration, resting and
exercise heart rates (HR), rating of perceived exertion
(RPE) using the Borg 6–20 scale,13 symptoms (dyspnoea
and/or angina) and electrocardiographic responses,
recorded throughout submaximal exercise testing. An
exercise test date was used to adjust for temporal trends
in pharmacological therapy and treatment of CHD.
Exercise adherence to CR and self-reported physical
activity were ascertained from attendance registers and
participant interview at the retest. Participants who
underwent exercise testing at baseline but did not
return for the retest (scheduled after 12 weeks of CR)
were identiﬁed as ‘non-completers’. These participants
typically attended no or few CR sessions.
sCRF was deﬁned in METs (1-MET ≈3.5 mL/kg/min),
estimated from the ﬁnal treadmill speed and grade
during submaximal exercise testing.14 The majority of
exercise tests were conducted using a progressive incre-
mental treadmill walking protocol.15 Participants exer-
cised up to an 85% age-predicted maximal heart rate
(or RPE 16–17), unless clinically contraindicated.16 For
participants exercising on the cycle ergometer (12%),
exercise time and ﬁnal work rate (Watts) were recorded
and the latter converted to estimated METs.17 These pro-
tocols were adopted as directly determined VO2 and HR
values for corresponding stages on the treadmill and
cycle ergometer have been shown to be highly corre-
lated (r=0.94 and r=0.89 for VO2 and HR, respectively),
indicating comparability between test modalities.15
Handrail support during treadmill testing was discour-
aged. Participants’ medications were not changed before
exercise testing and the same test modality used pre-CR
and post-CR.
There is no widely accepted clinical categorisation of
the sCRF phenotype in adults with CHD. In previous
epidemiological analyses, low, moderate and high CRF
has been deﬁned as the lower 20%, next 40% and
upper 40% of the exercise duration distribution.18 19
Sex-speciﬁc distributions of exercise test time in the
present study were assessed and the following categories
for low, moderate and higher sCRF determined; men
<8 min, 8–10 min and ≥11 min; women <5 min, 5–8 min
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and ≥9 min. In equivalent MET values, cut-offs were <6
METS and ≥8 METs (men), and <5 METs and ≥7 METS
(women). For comparison, sCRF was also analysed using
cut-offs published previously.2 7
Description of the CR programme
The exercise training component of the Heart Watch
CR programme has been fully described elsewhere.20 All
exercise sessions were formally supervised by exercise
instructors in a structured setting up to 5 days per week.
Participants received a mixed (aerobic and resistance)
circuit-based exercise of 24 min duration, with a 15 min
warm-up and 15 min cool-down. Aerobic exercises
included ﬂoor and treadmill walking, stepping, leg
cycling, arm-leg cycling and rowing ergometry.
Resistance and ﬂoor-based exercise sets involved eight
exercises performed for 30 s each. Participants were
strongly encouraged to attend classes on three non-
consecutive days and walk 30 min per day outside of the
programme. On the basis of resting and ﬁnal HR and
RPE from the exercise test, participants were prescribed
individual target heart rate training (between 40 and
85% heart rate reserve) with Polar heart rate monitors.
They were closely supervised by exercise instructors,
ensuring good adherence to exercise prescription.
Statistical analysis
Measures of central tendency and dispersion are re-
ported as mean and SD unless speciﬁed. All participant
characteristics at entry to CR (table 1) were compared
across sCRF categories using the χ2 test for categorical
variables and one-way analysis of variance (ANOVA) for
continuous variables (Kruskal-Wallis non-parametric
equivalent where appropriate). Characteristics of pro-
gramme completers and non-completers were compared
using independent t-tests. A mixed-model two-way
ANOVA was used to assess differences in exercise vari-
ables from baseline to follow-up (within-subject factors)
and between sCRF categories (between-subject factors)
with appropriate post hoc procedures. For variables that
were log transformed before modelling, the mean pre-
sented is the back transformed mean.
The primary outcome measure was all-cause mortality
at 14 years. Cox proportional hazard models were used
to determine the association between sCRF and sur-
vival.21 Clinically relevant variables with a p value<0.05
from univariate analysis were included in the multivari-
ate model. Logistic regression (backward stepwise) was
performed and HRs with 95% conﬁdence intervals
(95% CI) were reported. Age at initial test was adjusted
in years as a continuous variable. Estimated METs was
entered as a continuous variable and a categorical vari-
able. Receiver-operating characteristic (ROC) curves
were constructed to determine an optimal MET level
threshold for all-cause mortality.
A parsimonious approach to variable selection was
taken for multivariate analyses with 10 events per inde-
pendent variable analysed for model ﬁt.22 23 No
signiﬁcant collinearity (assessed using variance inﬂation
factors) was observed between variables selected for
models (all <1.5). Analyses were adjusted for age, waist
circumference and total cholesterol high-density lipopro-
tein cholesterol (TC/HDL-c) ratio (continuous vari-
ables); cardioprotective medications (antiplatelet
therapy, ACE inhibitors, (β)-blockers, diuretics and
statins), physical inactivity, diabetes, other CVD (chronic
heart failure, valvular disease, arrhythmia, vascular
disease), marital status, exercise ECG test result, date of
entry to CR (median split) and exercise test mode (all
categorical variables).
The χ2 statistic was used to assess the statistical import-
ance of each parameter for prediction of all-cause mor-
tality risk. A Kaplan-Meier survival plot was constructed,
with a log rank test to compare the time-dependent
occurrence of death in the groups stratiﬁed according to
sCRF categories at CR entry. The proportional hazards
assumption was veriﬁed as proportional over time with a
log(-log(survival)) plot versus log(time) plot for all vari-
ables. Continuous variables were categorised into groups
and model goodness-of-ﬁt shown to be well calibrated by
the Hosmer-Lemeshow test (p>0.05).
For variables of primary interest, no data were missing
from baseline and follow-up assessments. Missing data in
other variables accounted for <5% of the ﬁnal sample.
Analyses were performed using SPSS V.23.0 software
(SPSS Inc, Chicago, Illinois, USA).
RESULTS
Nine hundred and ninety-four participants (mean age
59.5; 76% male) were referred to CR. Participants who
died within 12 months of their baseline assessment
(n=7), those without complete follow-up (n=315) and
those without a valid baseline exercise test (n=2) were
excluded, leaving a ﬁnal study population of n=670. All
participants underwent baseline submaximal exercise
testing and medical assessment and had a minimum of
1 year of follow-up. Follow-up was complete to 1
November 2013.
Analysis of baseline sCRF and survival was based on
670 participants. Of these, n=465 (69%) also attended a
follow-up assessment after 14 weeks (median) CR. The
analysis of sCRF change is therefore based on 465 parti-
cipants with complete data from 2 exercise tests.
Participants without a follow-up test (‘non-completers’;
n=205, 31%) were subsequently compared to completers
in subgroup analysis. Female participants (n=136, 20%)
were excluded from ROC curve analysis as the sample
size did not support statistical analysis.
Participant characteristics
Table 1 describes the demographic and clinical
characteristics of the study participants based on sCRF at
entry to CR. One hundred and twenty-eight (19%) parti-
cipants were classiﬁed as having a low sCRF level, 317
(47%) a moderate sCRF level and 225 (34%) a higher
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sCRF level. Participants with low sCRF were older and
had a higher prevalence of positive exercise tests (ECG
abnormality/angina/severe dyspnoea), comorbidities
(including diabetes and obesity) and self-reported phys-
ical inactivity. Resting HR was also higher. There was a
higher prevalence of diuretic therapy use and lower use
of β-blocker therapy. Similar peak HR values on exercise
testing were attained for those on β-blocker therapy but
were higher for low and moderate sCRF groups in those
not on β-blockers. Peak ratings of RPE in the low sCRF
group tended to be lower than in participants with mod-
erate or higher sCRF. Secondary prevention medications
Table 1 Baseline demographic and clinical characteristics in n=670 participants stratified by sCRF category
Characteristic
Low sCRF
(n=128)†
Moderate sCRF
(n=317)
Higher sCRF
(n=225)‡ p Value
Age (years) 64 (9.7) 61 (8.7) 55 (8.6) <0.0005
Sex, male (%) 79 77 84 0.196
Elderly (age >75 years) (%) 12 3 0.0 <0.0005
Married/living with partner (%) 76 82 83 0.221
Previous MI (%) 31 32 42 0.029
Previous CABG (%) 43 46 35 0.052
Previous PCI (%) 13 14 16 0.575
Previous Angina (%) 27 29 20 0.050
Diabetes mellitus (%) 22 14 5 <0.0005
Hypertension (%) 11 16 14 0.461
Premature family history (%) 39 37 38 0.886
Chronic heart failure (%) 3 2 0.4 0.140
COPD (%) 0.8 2 1 0.804
Peripheral vascular disease (%) 3 0.9 0.4 0.071
Valvular disease (%) 10 5 4 0.053
Cerebrovascular disease (%) 0.0 1 0.4 0.305
BMI >30 (kg/m2) (%) 35 32 20 0.002
Waist circumference (cm) 100 (14) 98 (12) 95 (10) <0.0005
HDL cholesterol (mmol/L) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 0.508
Total cholesterol (mmol/L) 5.3 (1.1) 5.6 (1.2) 5.5 (1.1) 0.092
TC/HDL ratio 4.8 (1.7) 4.9 (1.5) 4.8 (1.5) 0.828
LDL cholesterol (mmol/L) 3.3 (1.1) 3.5 (1.1) 3.5 (1.0) 0.198
Triglycerides (mmol/L) (LOG10) 1.5 1.6 1.5 0.212
Previous (<10 years/current smoker) (%) 36 35 40 0.467
Physically inactive (%) 41 29 20 <0.0005
SBP rest (mm Hg) 144 (21) 146 (22) 138 (20) <0.0005
DBP rest (mm Hg) 83 (11) 86 (12) 86 (11) 0.399
HR Rest (bpm) 75 (16) 72 (16) 63 (13) 0.007
ACE Inhibitor (%) 24 22 16 0.170
Antiplatelet therapy (%) 68 75 77 0.138
β-Blocker (%) 34 39 52 0.002
Diuretic (%) 40 25 9 <0.0005
Statin (%) 41 37 39 0.630
Exercise test characteristics
Test time (min), median (IQR) 6 (4–6) 8 (8–10) 12 (12–14) <0.0005
Power output (Watts) 71 (16) 106 (17) 145 (10) <0.0005
Exercise mode (treadmill) (%) 87 89 89 0.794
Peak HR (% APMHR) 94 (14) 95 (9) 92 (8) 0.008
Peak HR β-blocked (% APMHR) 92 (21) 93 (15) 95 (12) 0.219
Peak RPE 14 (1.8) 15 (1.7) 15 (1.7) <0.0005
Peak RPE (β-blocked) 14 (1.7) 16 (1.4) 15 (1.5) <0.0005
Estimated METs, median (IQR) 5 (3.7–5) 6.1 (6.1–7) 8.3 (8.3–9.6) <0.0005
Positive exercise test (ECG) (%) 21 13 5 <0.0005
Results presented as mean (SD) unless otherwise stated.
†Entry sCRF level <6 METs (men) and <5 METs (women).
‡Entry sCRF level ≥8 METs and ≥7 METs (women).
APMHR, age-predicted maximum heart rate; BMI, body mass index; bpm, beats per minute; CABG, coronary artery bypass graft; COPD,
chronic obstructive pulmonary disease; DBP, diastolic blood pressure; ECG, electrocardiogram; HDL, high-density lipoprotein; HR, heart rate;
LDL, low-density lipoprotein; METs, metabolic equivalents; MI, myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic
blood pressure; TC/HDL, total cholesterol high-density lipoprotein cholesterol ratio.
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prescribed in the cohort overall were: β-blockers 48%,
antiplatelet therapy (mainly aspirin) 81%, statin therapy
38%, diuretics 23% and ACE inhibitors 20%. These were
consistent for all participants between CR entry and
follow-up.
Two-hundred and ﬁve participants (31%) in the study
cohort did not attend initial reassessment following CR.
Reasons for non-completion were not recorded; how-
ever, participants not completing were younger (58±10
vs 60±9 years) and less likely to have undergone previous
CABG surgery. ‘Non-completers’ were also more likely
to be physically inactive (36% vs 24%) and a current/
previous smoker (all p<0.05). Since groups were similar
with respect to survival and all other baseline character-
istics, including sCRF, both groups were included in
survival analysis.
sCRF at CR entry and all-cause mortality risk
Clinical predictors of all-cause mortality from Cox pro-
portional hazards models are presented in table 2. After
a median follow-up of 14 years (range, 1.2 years–
19.4 years), 206 deaths (31%) were recorded: 54% in
the low sCRF group (n=69 deaths), 31% in the moderate
sCRF group (99=deaths) and 17% in the higher sCRF
group (n=38 deaths). Baseline sCRF was 7.1±1.8 METs
among survivors and 6.1±1.7 METs in decedents
(p<0.0005). Signiﬁcant univariate predictors of all-cause
death were low baseline sCRF level, age, abnormal exer-
cise test response, co-existing CVD disorders, physical
inactivity and taking speciﬁc cardioprotective medication
(diuretics, statin and ACE-inhibitors).
Sex, smoking status (including never, former or
current), previous MI, body mass index, β-blocker medi-
cation use, resting systolic blood pressure, non-completer
status and indices of multiple social deprivation were
not univariate predictors of all-cause mortality (p>0.05)
in this cohort.
For the cohort overall, age-adjusted mortality risk was
17% lower for each 1-MET increment in sCRF at CR
entry (HR 0.83; 95% CI 0.76 to 0.90). In multivariate-
adjusted analysis, mortality risk was 11% lower per
1-MET increment (HR 0.89; 95% CI 0.81 to 0.98).
Relative mortality risks across sCRF categories are pre-
sented in table 3 and survival plot in ﬁgure 1. Compared
to the low sCRF group, all models (unadjusted,
age-adjusted and multivariate-adjusted) demonstrated
signiﬁcantly lower HRs for moderate and higher sCRF
groups. Mortality risk was 41% lower for those with mod-
erate sCRF (HR 0.59; 95% CI 0.42 to 0.83), and 60%
lower for those with higher sCRF (HR 0.40; 95% CI 0.25
to 0.64), representing a more than two-fold increase
in relative risk of death for participants with low sCRF
compared to their higher ﬁt counterparts.
In secondary analysis, thresholds used previously to
examine the prognostic role of CRF were compared to
our distributional analysis (see online supplementary
table S1). Univariate and multivariate analysis conﬁrmed
sCRF as an independent predictor of all-cause mortality.
sCRF change and all-cause mortality risk
Of the 465 participants who attended baseline and
follow-up assessment, a further n=49 were excluded
from the subgroup analysis of sCRF change following
CR. Reassessments for these participants were delayed,
and thus exercise test data were potentially unrepresen-
tative of sCRF status following CR. Data presented are
from n=416 participants with two valid exercise tests
pre-CR and post-CR. The mean weekly frequency of
exercise training (2±1 sessions) and the total number of
sessions attended (28±9 sessions were not signiﬁcantly
different between low, moderate, and higher sCRF
groups (both p>0.05).
Following 14 weeks of exercise-based CR, sCRF values
improved across the cohort (0.82 MET improvement;
p<0.0005), with no signiﬁcant difference between males
and females (0.83 vs 0.79 METs, respectively). The
majority of participants improved or at least maintained
their sCRF classiﬁcation at follow-up (table 4). Notably,
69% with low baseline ﬁtness and 45% with moderate
baseline ﬁtness improved classiﬁcation.
However, there was a differential mean sCRF improve-
ment (based on estimated METs and exercise time)
across sCRF groups (table 5). A signiﬁcantly higher
mean improvement was evident in the low sCRF cat-
egory (1.36 METs; 95% CI 1.07 to 1.64) compared to
both the moderate (0.99 METs; 95% CI 0.85 to 1.13)
and higher sCRF groups (0.31 METs; 95% CI 0.12 to
0.50). There was no difference in peak HR across
groups. Among participants in the low sCRF category,
each 1-MET improvement was associated with a 27%
lower age-adjusted risk of mortality (HR 0.73; 95% CI
0.57 to 0.94). In contrast, there was no signiﬁcant risk
Table 2 Survival estimates from multivariate Cox
regression analysis for all-cause mortality
Variable HR (95% CI) χ2 p Value
All-cause mortality (n=670)
Other CVD 2.07 (1.45 to 2.93) 16.4 <0.0005
Age 1.03 (1.02 to 1.05) 15.1 <0.0005
Higher sCRF† 0.40 (0.25 to 0.64) 14.7 <0.0005
ACE-inhibitor use 1.85 (1.34 to 2.57) 13.8 <0.0005
Date of CR entry 1.74 (1.25 to 2.41) 10.9 0.001
Statin use 1.62 (1.18 to 2.22) 8.9 0.003
Antiplatelet
therapy use
0.66 (0.48 to 0.92) 5.9 0.015
Married/living with
partner
0.66 (0.47 to 0.92) 5.9 0.016
Diuretic use 1.35 (0.97 to 1.87) 3.2 0.075
Univariate predictors: diabetes, physical inactivity, exercise test
modality, entry METs, TC/HDL-c ratio, waist circumference, resting
heart rate were no longer significant predictors in the multivariate
model.
†Entry sCRF level ≥8 METs (men) and ≥7 METs (women).
CVD, cardiovascular disease; CR, cardiac rehabilitation; METs,
metabolic equivalents; TC/HDL-c total cholesterol high-density
lipoprotein-cholesterol ratio; sCRF, submaximal cardiorespiratory
fitness.
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reduction associated with estimated MET gain for mod-
erately ﬁt (HR 0.77; 95% CI 0.59 to 1.01) or higher-ﬁt
(HR 0.95; 95% CI 0.68 to 1.33) groups. The highest rela-
tive risk of mortality was observed in participants classi-
ﬁed as low ﬁt at CR entry and follow-up (n=23; HR 7.94;
95% CI 4.28 to 14.75).
To determine the optimal discriminatory accuracy of
sCRF for predicting all-cause mortality in this cohort, a
ROC curve analysis was also performed (restricted to
males; n=534). The optimal sCRF threshold was 6.5
METs (area under the curve 0.71 (0.66 to 0.76); sensitiv-
ity 67% and speciﬁcity 63%). This threshold was used to
deﬁne lower (≤6.5 METs) and higher (>6.5 METs) sCRF
categories. After age, a higher sCRF level was the highest
ranking predictor of all-cause mortality (table 6).
Self-reported physical inactivity at CR entry was a multi-
variate predictor in male-only analyses.
DISCUSSION
To the best of our knowledge, this is the most detailed
evaluation of prognostic risk associated with sCRF at
entry to CR and the ﬁrst UK study to examine the
relationship between short-term sCRF changes and all-
cause mortality among participants attending a
community-based programme. Our data demonstrate
that initial sCRF level was the strongest modiﬁable pre-
dictor of long-term survival, surpassed only by older age
and co-existing CVD. This relationship remained follow-
ing adjustment for a number of important confounders
not previously considered in UK CR studies, including
coronary risk factors and self-reported physical inactivity.
Moreover, for the lowest-ﬁt individuals, we report a quan-
tiﬁable reduction in all-cause mortality risk per MET
increase in sCRF achieved during exercise-based CR.
This may be clinically important given the higher base-
line mortality risk of this group compared to their
higher ﬁt counterparts.
Our data compare favourably with previous inter-
national studies employing maximal exercise testing and
demonstrating an association between CRF and progno-
sis in patients with CHD.1 2 4 In a study of 2812 patients
entering CR between 1996 and 2004 by Keteyian et al,4
each 1 mL/kg/min increment in the estimated VO2
peak at baseline demonstrated a ∼15% lower risk for
all-cause mortality. When extrapolated to 1-MET (HR
Table 3 Comparison of HRs for all-cause mortality between low, moderate and higher sCRF participants at CR entry
(n=670)
All-cause mortality
(n=206 deaths)
Low sCRF*
(referent) (n=128)
Moderate sCRF
HR (95% CI) (n=317) p Value
Higher sCRF†
HR (95% CI) (n=225) p Value
Model 1: unadjusted 1.00 0.50 (0.37 to 0.68) <0.0005 0.25 (0.17 to 0.37) <0.0005
Model 2: adjusted for age 1.00 0.55 (0.40 to 0.75) <0.0005 0.35 (0.23 to 0.53) <0.0005
Model 3: adjusted for covariates 1.00 0.59 (0.42 to 0.83) 0.002 0.40 (0.25 to 0.64) <0.0005
Model 3 covariates were as follows: age; ACE-inhibitor, statin, diuretic, antiplatelet therapy use; diabetes, other CVD, waist circumference,
TC/HDL ratio, date of CR entry, marital status, physical inactivity, resting heart rate, exercise test mode and negative exercise test (ECG).
*Entry sCRF level <6 METs (men) and <5 METs (women) at CR entry.
†Entry sCRF level ≥8 METs (men) and ≥7 METs (women) at CR entry.
CVD, cardio vascular disease; CR, cardiac rehabilitation; METs, metabolic equivalents; TC/HDL, total cholesterol high-density lipoprotein
ratio; sCRF, submaximal cardiorespiratory fitness.
Figure 1 Kaplan-Meier plot showing risk of all-cause
mortality in participants stratified by baseline sCRF (log-rank
test; p<0.0005). sCRF, submaximal cardiorespiratory fitness.
Table 4 sCRF reclassification from baseline to follow-up
after 14 weeks CR (n=416)
sCRF classification at follow-up after
CR (%)
sCRF
classification
at CR entry
Improved*
sCRF
Maintained†
sCRF
Worsened
sCRF
Low sCRF
(n=74)
69 31 −
Moderate
sCRF (n=196)
45 53 2
Higher sCRF
(n=146)
− 91 9
*Defined as improving sCRF to a higher sCRF category between
the baseline and follow-up test.
†Defined as no change in the sCRF category from the baseline to
the follow-up test.
CR, cardiac rehabilitation; sCRF, submaximal cardiorespiratory
fitness.
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0.853.5=0.57), this represents a reduction in risk equiva-
lent to 43% per MET. In a more recent study of patients
with CVD referred for clinical exercise testing, Mandic
et al5 estimated a more modest 11% reduction in all-
cause mortality risk with each 1-MET advantage in VO2
peak. The variance in risk estimates attributed to CRF
between observational investigations is most likely due to
differences in cohort characteristics, medical and sec-
ondary prevention treatments and exercise testing
modalities (ie, maximal vs submaximal exercise proto-
cols). It is also likely to reﬂect the variability in thresh-
olds used to deﬁne low and high CRF categories,1 5 7
given that there is currently no consensus for the clinical
categorisation of CRF in patients with CHD.
Our data extend ﬁndings from the only other pub-
lished study to examine the ﬁtness-mortality relationship
in patients undertaking CR within the UK.9 In that
study, CRF was estimated from maximal testing in a
cohort of predominantly post-MI patients (86% men,
age 61 years) over a shorter follow-up (mean 10.7 years).
Low CRF at entry and CRF improvement during
once-or-twice weekly CR were strong predictors of sur-
vival. However, since neither relationship was expressed
in the context of survival beneﬁt per MET increment in
exercise capacity, it is not possible to quantify the
change in ﬁtness comparable with international studies.
The overall improvement in sCRF within our cohort
(0.82 MET) is analogous to that estimated during
maximal testing by Barons et al (1.08 METs) and congru-
ent with the ∼0.5 MET improvement estimated by
Sandercock et al8 in 950 patients undergoing submaxi-
mal testing across four UK CR centres.
To the best of our knowledge, this is the ﬁrst UK study to
report a quantiﬁable dose–response to CR exercise train-
ing, with a 27% reduction in all-cause mortality risk per
MET increase achieved by the lowest ﬁt. It substantiates
the ﬁndings of Martin et al 6 from the Cardiac Wellness
Institute of Calgary who estimated 1.41 METs, 1.01 METs
and 0.80 MET improvements from maximal testing, for
low, moderate and high CRF groups, respectively in their
large cohort (76% men, age 60 years). These investigators
also found that each MET gain during CR was associated
with a 30% point reduction in mortality risk for the least
ﬁt patients (<5 METs). This is similar to the 27%
age-adjusted risk reduction in the lowest sex-speciﬁc sCRF
groups (<5 METs women, <6 METs men) we report. In
contrast, Barons et al 9 reported no signiﬁcant risk reduc-
tion associated with improvement from low to moderate
ﬁtness during CR. Others assessing the relationship
between submaximal exercise training workload in CR
and medium-term survival (mean 4.4 years) have esti-
mated a 28% age-adjusted reduction in mortality risk per
MET increase over 12 weeks (36 sessions).24
It is noted that medical therapies used in several previ-
ous observational studies either antedated the contem-
porary use of cardioprotective pharmacotherapies, or
patients were not treated rigorously with available second-
ary preventative medications. Our ﬁnding that certain
cardioprotective medications, notably ACE inhibitor;1 9
diuretics1 3 and statins,5 were independent adverse pre-
dictors of all-cause mortality has been shown previously.
Higher CRF associated with improved survival in hyperlip-
idaemic men and women has been shown to affect the
positive risk reduction from statin therapy in those with
established CHD within the Henry Ford Exercise Testing
cohort.25 There are limited previous data to support our
observation that β-blockade does not interfere with the
prognostic signiﬁcance of low exercise capacity in patients
Table 5 Mean changes in exercise test variables from baseline to follow-up after 14 weeks CR (n=416)
Exercise test characteristics Low sCRF† (n=76) Moderate sCRF (n=196) Higher sCRF‡ (n=146) p Value
Change in METs 1.36 (1.07 to 1.64) 0.99 (0.85 to 1.13) 0.31 (0.12 to 0.50) <0.0005
Change in exercise time (min) 2.4 (1.9 to 3.0) 1.6 (1.4 to 1.8) 0.5 (0.2 to 0.8) <0.0005
Change in power output (W) 38 (26 to 53) 20 (11 to 26) 10 (0.7 to 20) 0.122
Change in peak HR (bpm) −1 (−1 to 0) 1 (1 to 1) 0 (0 to 0) 0.761
Change in peak HR (β-blocked) 5 (5 to 6) 4 (4 to 4) 4 (3 to 4) 0.786
†Entry sCRF level <6 METs (men) and <5 METs (women) at CR entry.
‡Entry sCRF level ≥8 METs (men) and ≥7 METs (women) at CR entry.
bpm, beats per minute; CR, cardiac rehabilitation; sCRF, submaximal cardiorespiratory fitness; METs, metabolic equivalents; W, Watts.
Table 6 Survival estimates from multivariate Cox
regression analysis for all-cause mortality among males
(n=534)
Variable HR (95% CI) χ2 p Value
All-cause mortality
Age 1.04 (1.02 to 1.06) 16.5 <0.0005
Higher sCRF† 0.39 (0.23 to 0.66) 14.7 <0.0005
Other CVD 1.99 (1.37 to 2.90) 12.8 <0.0005
Statin use 1.78 (1.29 to 2.47) 12.2 <0.0005
Antiplatelet
therapy use
0.58 (0.41 to 0.82) 9.6 0.002
Diuretic therapy
use
1.71 (1.20 to 2.45) 8.7 0.003
ACE-inhibitor use 1.53 (1.07 to 2.20) 5.5 0.020
Physically
inactive‡
1.46 (1.04 to 2.05) 4.7 0.030
†Entry sCRF level >6.5 METs.
‡Self-reported sedentary.
CVD, cardiovascular disease; sCRF, submaximal
cardiorespiratory fitness; METs, metabolic equivalents.
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with CR.7 The observational ﬁndings of adverse risks asso-
ciated with cardioprotective therapies are contrary to
strong randomised controlled trial evidence26–28 demon-
strating the efﬁcacy of these treatments for secondary pre-
vention of CHD and may reﬂect differences in severity of
underlying disease and prevalence of comorbidities
among individuals receiving these treatments.
This is a retrospective study with a number of limita-
tions. The use of prespeciﬁed (submaximal) test termin-
ation criteria (attainment of 85% age-predicted maximal
heart rate) is acknowledged to be inferior to the meas-
urement (or estimation) of VO2 peak and equivalent
MET levels from maximal testing, and so our results do
not reﬂect participants’ individualised peak aerobic cap-
acity. Further, while the MET is a widely used physio-
logical metric, its limitations are acknowledged.29
Unmeasured confounders remain a limitation associated
with all observational study designs and measures that
may have been relevant to the current analysis, such as
compliance with home exercise during CR, were not cap-
tured in the Heart Watch database. In addition, we are
not able to report why CR non-completers left the pro-
gramme, as precise reasons were not routinely recorded.
CONCLUSIONS
Our results demonstrate the strong prognostic value of
sCRF and the risk reduction associated with higher
levels of sCRF in men and women starting exercise-
based CR, irrespective of other important markers of
risk. Importantly, for the lowest-ﬁt individuals, increasing
sCRF through exercise-based CR may be associated with
signiﬁcant additional survival beneﬁt, reinforcing the
clinical importance of moving patients out of this higher
risk group. These patients may also beneﬁt most from
early identiﬁcation and closer monitoring by CR staff
through serial exercise testing.
Accessible data from submaximal exercise test per-
formance (with electrocardiographic analysis) may yield
important prognostic information for the assessment of
sCRF and the risk stratiﬁcation of patients undertaking
community-based CR within the UK. These data may
help clinicians and CR practitioners improve the design
of structured, supervised exercise training services tai-
lored to maximise CRF gains for the least ﬁt patients
and thus, improve long-term survival following CR.
Twitter Follow Claire Taylor at @claire007RM
Contributors CTa, CTs, KKW, SC and LI contributed to the study design. CTa,
SC, CTs, JM, JWM and MD collected the data. CTa, LI and SC were involved
in editing and data preparation. CTa performed the data analysis. CTa, SC and
LI contributed to the first draft of the manuscript. CTs, SC and LI read and
critically appraised several versions of the manuscript. CTa had full access to
the data in the study. CTa is the guarantor. All authors have critically revised
the manuscript for important intellectual content and provided final approval
of the version for publication.
Funding This research received no specific grant from any funding agency in
the public, commercial or not-for-profit sectors.
Competing interests None declared.
Ethics approval Approval for this study was granted in 2013 from Yorkshire
and the Humber (Leeds East) Local Research Ethics Committee via the
Integrated Research Application Service (reference 13/YH/0099) and
permission to retrospectively access prespecified data from medical records
without participants’ prior consent was obtained from the Health Research
Authority Confidentiality Advisory Group (reference CAG 5-03(PR6)/2013).
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement A technical appendix will be made freely available at
https://hydra.hull.ac.uk/resources/hull:12907 via the University of Hull Digital
Research Data Repository (Hydra).
Open Access This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://
creativecommons.org/licenses/by/4.0/
REFERENCES
1. Kavanagh T, Mertens DJ, Hamm LF, et al. Prediction of long-term
prognosis in 12 169 men referred for cardiac rehabilitation.
Circulation 2002;106:666–71.
2. Kavanagh T, Mertens J, Hamm LF, et al. Peak oxygen intake and
cardiac mortality in women referred for cardiac rehabilitation. J Am
Coll Cardiol 2003;42:2139–43.
3. Vanhees L, Fagard R, Thijs L, et al. Prognostic significance of peak
exercise capacity in patients with coronary artery disease. J Am Coll
Cardiol 1994;23:358–63.
4. Keteyian SJ, Brawner CA, Savage PD, et al. Peak aerobic capacity
predicts prognosis in patients with coronary heart disease. Am Heart
J 2008;156:292–300.
5. Mandic S, Myers J, Oliveira RB, et al. Characterizing differences in
mortality at the low end of the fitness spectrum in individuals with
cardiovascular disease. Eur J Cardiovasc Prev Rehabil
2010;17:289–95.
6. Martin BJ, Arena R, Haykowsky M, et al. Cardiovascular fitness and
mortality after contemporary cardiac rehabilitation. Mayo Clin Proc
2013;88:455–63.
7. Myers J, Prakash M, Froelicher VF, et al. Exercise capacity and
mortality among men referred for exercise testing. N Engl J Med
2002;346:793–801.
8. Sandercock GR, Cardoso F, Almodhy M, et al. Cardiorespiratory
fitness changes in patients receiving comprehensive outpatient cardiac
rehabilitation in the UK: a multicentre study. Heart 2013;99:785–90.
9. Barons MJ, Turner S, Parsons N, et al. Fitness predicts long-term
survival after a cardiovascular event: a prospective cohort study.
BMJ Open 2015;5:e007772.
10. West RR, Jones DA, Henderson AH. Rehabilitation after myocardial
infarction trial (RAMIT): multi-centre randomised controlled trial of
comprehensive cardiac rehabilitation in patients following acute
myocardial infarction. Heart 2012;98:637–44.
11. Sandercock G, Hurtado V, Cardoso F. Changes in cardiorespiratory
fitness in cardiac rehabilitation patients: a meta-analysis. Int J
Cardiol 2013;167:894–902.
12. Piepoli MF, Corra U, Benzer W, et al. Secondary prevention through
cardiac rehabilitation: from knowledge to implementation. A position
paper from the cardiac rehabilitation section of the European
Association of Cardiovascular Prevention and Rehabilitation. Eur J
Cardiovasc Prev Rehabil 2010;17:1–17.
13. Borg GA. Psychophysical bases of perceived exertion. Med Sci
Sports Exerc 1982;14:377–81.
14. Givoni B, Goldman RF. Predicting metabolic energy cost. J Appl
Physiol 1971;30:429–33.
15. Lehmann G, Schmid S, Ammer R, et al. Evaluation of a new
treadmill exercise protocol. Chest 1997;112:98–106.
16. Pescatello LS, Arena R, Riebe D, et al. Guidelines for exercise
testing and prescription. 9th edn. Baltimore, MD: Lippincott Williams
& Wilkins, 2010.
17. Astrand PO, Ryhming I. A nomogram for calculation of aerobic
capacity (physical fitness) from pulse rate during sub-maximal work.
J Appl Physiol 1954;7:218–21.
18. Sui X, LaMonte MJ, Blair SN. Cardiorespiratory fitness and risk of
nonfatal cardiovascular disease in women and men with
hypertension. Am J Hypertens 2007;20:608–15.
19. Blair SN, Kampert JB, Kohl HW 3rd, et al Influences of
cardiorespiratory fitness and other precursors on cardiovascular
disease and all-cause mortality in men and women. JAMA
1996;276:205–10.
8 Taylor C, et al. BMJ Open 2016;6:e011125. doi:10.1136/bmjopen-2016-011125
Open Access
20. Carroll S, Tsakirides C, Hobkirk J, et al. Differential
improvements in lipid profiles and Framingham recurrent risk
score in patients with and without diabetes mellitus undergoing
long-term cardiac rehabilitation. Arch Phys Med Rehabil
2011;92:1382–7.
21. Cox DR, Oakes D. Analysis of survival data. Boca Raton, Florida:
Chapman & Hall/CRC, 1984.
22. Concato J, Peduzzi P, Holford TR, et al. Importance of events per
independent variable in proportional hazards analysis. I. Background,
goals, and general strategy. J Clin Epidemiol 1995;48:1495–501.
23. Peduzzi P, Concato J, Feinstein AR, et al. Importance of events per
independent variable in proportional hazards regression analysis. II.
Accuracy and precision of regression estimates. J Clin Epidemiol
1995;48:1503–10.
24. Feuerstadt P, Chai A, Kligfield P. Submaximal effort tolerance as a
predictor of all-cause mortality in patients undergoing cardiac
rehabilitation. Clin Cardiol 2007;30:234–8.
25. Hung RK, Al-Mallah MH, Qadi MA, et al. Cardiorespiratory
fitness attenuates risk for major adverse cardiac events in
hyperlipidemic men and women independent of statin therapy:
the Henry Ford ExercIse Testing Project. Am Heart J
2015;170:390–9.
26. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of
cholesterol-lowering treatment: prospective meta-analysis of data
from 90,056 participants in 14 randomised trials of statins. Lancet
2005;366:1267–78.
27. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors,
calcium antagonists, and other blood pressure-lowering drugs:
results of prospectively designed overviews of randomised trials.
Lancet 2000;355:1955–64.
28. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane
Database Syst Rev 2009(3):CD001841.
29. Byrne NM, Hills AP, Hunter GR, et al. Metabolic equivalent: one size
does not fit all. J Appl Physiol 2005;99:1112–19.
Taylor C, et al. BMJ Open 2016;6:e011125. doi:10.1136/bmjopen-2016-011125 9
Open Access
